Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Caris Life Sciences,�Inc. (CAI) vs ImmunityBio, Inc. (IBRX)

Caris Life Sciences,�Inc. and ImmunityBio, Inc. are both Biotechnology companies. Caris Life Sciences,�Inc. and ImmunityBio, Inc. are of similar size ($9.2B and $9.1B). ImmunityBio, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 85.1×. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 96.4%. Caris Life Sciences,�Inc. has the higher net margin (8.15% vs −598.6%) and the higher return on invested capital (50.0% vs 0.00%). Across the 16 metrics below, Caris Life Sciences,�Inc. leads on 11 and ImmunityBio, Inc. on 5.

Valuation

Metric CAI IBRX Biotechnology median
P/E 85.08 n/m 7.88
P/S 9.14 53.46 11.47
P/B 15.29 n/m 2.52
Price to free cash flow 72.98 n/m 21.16
EV/EBITDA 48.03 n/m 0.74
EV/Sales 8.74 56.01 10.73
Earnings yield 1.18% (11.49%) (28.84%)
Free cash flow yield 1.37% (3.25%) (23.03%)

Profitability

Metric CAI IBRX Biotechnology median
Gross margin 69.66% 99.34% 65.16%
Operating margin 15.49% (151.88%) 0.00%
Net margin 8.15% (598.56%) 0.00%
Free cash flow margin 12.53% (173.76%) 0.00%
Return on equity 15.45% 122.85% (57.72%)
Return on assets 7.39% (192.58%) (49.22%)
Return on invested capital 49.95% 0.00% 0.00%

Growth

Metric CAI IBRX Biotechnology median
Revenue growth (TTM) 96.36% 192.92% 5.64%
EPS growth (last fiscal year) 59.45% 38.71% —
Revenue growth, 5-year CAGR — 184.76% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI IBRX Biotechnology median
Debt to equity 0.66 (0.74) 0.00
Current ratio 5.53 5.72 4.73
Net debt to EBITDA (5.23) (0.97) 0.96

Dividend

Metric CAI IBRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric CAI IBRX Biotechnology median
Market cap 9.12b 9.19b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack